KR102852282B1 - 면역원성 조성물 - Google Patents

면역원성 조성물

Info

Publication number
KR102852282B1
KR102852282B1 KR1020217016698A KR20217016698A KR102852282B1 KR 102852282 B1 KR102852282 B1 KR 102852282B1 KR 1020217016698 A KR1020217016698 A KR 1020217016698A KR 20217016698 A KR20217016698 A KR 20217016698A KR 102852282 B1 KR102852282 B1 KR 102852282B1
Authority
KR
South Korea
Prior art keywords
pertussis
toxoid
immunogenic composition
omv
omvs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217016698A
Other languages
English (en)
Korean (ko)
Other versions
KR20210090646A (ko
Inventor
마리오 콘토르니
마리아그라찌아 피짜
안야 서버트
Original Assignee
글락소스미스클라인 바이오로지칼즈 에스.에이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 바이오로지칼즈 에스.에이. filed Critical 글락소스미스클라인 바이오로지칼즈 에스.에이.
Publication of KR20210090646A publication Critical patent/KR20210090646A/ko
Application granted granted Critical
Publication of KR102852282B1 publication Critical patent/KR102852282B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/5555—Muramyl dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020217016698A 2018-11-06 2019-11-04 면역원성 조성물 Active KR102852282B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18204691 2018-11-06
EP18204691.2 2018-11-06
PCT/EP2019/080120 WO2020094580A1 (en) 2018-11-06 2019-11-04 Immunogenic compositions

Publications (2)

Publication Number Publication Date
KR20210090646A KR20210090646A (ko) 2021-07-20
KR102852282B1 true KR102852282B1 (ko) 2025-09-01

Family

ID=64456746

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217016698A Active KR102852282B1 (ko) 2018-11-06 2019-11-04 면역원성 조성물

Country Status (14)

Country Link
US (2) US12128094B2 (enExample)
EP (1) EP3876982A1 (enExample)
JP (1) JP7469302B2 (enExample)
KR (1) KR102852282B1 (enExample)
CN (1) CN112996538B (enExample)
AR (1) AR117191A1 (enExample)
AU (1) AU2019376832B2 (enExample)
BR (1) BR112021007668A2 (enExample)
CA (1) CA3117867A1 (enExample)
EA (1) EA202190914A1 (enExample)
IL (1) IL282753B2 (enExample)
MX (1) MX2021005303A (enExample)
SG (1) SG11202103389WA (enExample)
WO (1) WO2020094580A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240082379A1 (en) 2020-12-11 2024-03-14 Glaxosmithkline Biologicals Sa Hyper-Blebbing Bacteria
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process
CN119524117B (zh) * 2025-01-23 2025-09-23 康希诺生物股份公司 免疫原性组合物、百白破联合疫苗及其制备方法和应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014155294A1 (en) * 2013-03-27 2014-10-02 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Vaccines for the prevention of infections with bordetella
US20160051554A1 (en) * 2011-11-30 2016-02-25 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2018098362A1 (en) * 2016-11-23 2018-05-31 Gritstone Oncology, Inc. Viral delivery of neoantigens

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
ATE127347T1 (de) 1989-04-28 1995-09-15 Sclavo Spa Pertussistoxin-mutanten, dieselbe produzierende bordetella-stämme und ihre verwendung als vakzin gegen pertussis.
IT1248735B (it) * 1990-06-21 1995-01-26 Sclavo Spa Vaccini acellulari contro la pertosse
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
EP1034792A1 (en) 1999-03-11 2000-09-13 Pasteur Merieux Serums Et Vaccins Intranasal delivery of pneumococcal polysaccharide vaccines
FR2791895B1 (fr) 1999-03-23 2001-06-15 Pasteur Merieux Serums Vacc Utilisation de trehalose pour stabiliser un vaccin liquide
DE60039450D1 (de) 1999-12-02 2008-08-21 Novartis Vaccines & Diagnostic Zusammensetzungen und methoden zur stabilisierung von biologischen molekülen nach lyophilisierung
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
RU2323002C2 (ru) 2001-07-26 2008-04-27 Чирон Срл. Вакцины, содержащие алюминиевые адъюванты и гистидин
US20060057160A1 (en) 2002-08-02 2006-03-16 Ralph Biemans Vaccine composition
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
BR112014014950B1 (pt) * 2011-12-21 2022-03-29 Bionet-Asia, Co. Ltd Cepa de bordetella pertussis geneticamente modificada, e, métodos para produzir uma cepa de bordetella pertussis modificada e para produzir antígenos de bordetella pertussis
RU2015106791A (ru) * 2012-10-03 2016-11-20 Глэксосмитиклайн Байолоджикалз Са Иммуногенные композиции
WO2014135651A1 (en) 2013-03-08 2014-09-12 Crucell Holland B.V. Acellular pertussis vaccine
MX2016001695A (es) 2013-08-05 2016-05-02 Glaxosmithkline Biolog Sa Composiciones inmunogenas de combinacion.
ES2992907T3 (en) 2017-03-13 2024-12-19 Intravacc B V Bordetella vaccines comprising lps with reduced reactogenicity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160051554A1 (en) * 2011-11-30 2016-02-25 Emory University Antiviral jak inhibitors useful in treating or preventing retroviral and other viral infections
WO2014155294A1 (en) * 2013-03-27 2014-10-02 Consejo Nacional De Investigaciones Cientificas Y Tecnicas (Conicet) Vaccines for the prevention of infections with bordetella
WO2018098362A1 (en) * 2016-11-23 2018-05-31 Gritstone Oncology, Inc. Viral delivery of neoantigens

Also Published As

Publication number Publication date
AU2019376832B2 (en) 2024-01-25
IL282753A (en) 2021-06-30
CA3117867A1 (en) 2020-05-14
MX2021005303A (es) 2021-07-07
JP2022506347A (ja) 2022-01-17
US20230201325A1 (en) 2023-06-29
US20250049906A1 (en) 2025-02-13
CN112996538B (zh) 2025-07-08
US12128094B2 (en) 2024-10-29
IL282753B2 (en) 2025-04-01
JP7469302B2 (ja) 2024-04-16
AU2019376832A1 (en) 2021-05-13
EA202190914A1 (ru) 2021-08-03
KR20210090646A (ko) 2021-07-20
SG11202103389WA (en) 2021-05-28
EP3876982A1 (en) 2021-09-15
BR112021007668A2 (pt) 2021-07-27
AR117191A1 (es) 2021-07-21
IL282753B1 (en) 2024-12-01
CN112996538A (zh) 2021-06-18
WO2020094580A1 (en) 2020-05-14

Similar Documents

Publication Publication Date Title
US20250049906A1 (en) Immunogenic compositions
EA016417B1 (ru) Способ получения вакцины
JP2019068864A (ja) 過剰ブレブ形成Ｓｈｉｇｅｌｌａ株
JP6266631B2 (ja) 免疫原性組成物
JP2019163284A (ja) 併用免疫原性組成物
EP2879704A1 (en) Method for eliciting in infants an immune response against rsv and b. pertussis
CN105473603B (zh) 用于登革病毒疫苗的方法与组合物
JP7650871B2 (ja) 免疫原性組成物
CA2894260A1 (en) Conjugates for protecting against diphtheria and/or tetanus
JP2015536929A (ja) スタフィロコッカス・アウレウスｓｄｒｅｃｎａｂドメイン及びワクチン接種のためのその使用
EA045827B1 (ru) Иммуногенные композиции
EA048463B1 (ru) Иммуногенные композиции

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)